Review Question - QID 109755

A 53-year-old man with recurrent pancreatic adenocarcinoma is enrolled in a clinical trial for a novel chemotherapeutic agent that his physician believes may be beneficial to his condition. The novel drug was previously tested in a small population and is now undergoing a larger phase 3 trial in preparation for FDA approval. A dose-response trial had the following results:

10 mg dose - 6/59 patients demonstrated improvement
20 mg dose - 19/49 patients demonstrated improvement
30 mg dose - 26/53 patients demonstrated improvement
40 mg dose - 46/51 patients demonstrated improvement

The same trial also had the following safety profile:

20 mg dose - 5/49 patients had a treatment related adverse event
40 mg dose - 11/51 patients had a treatment related adverse event
60 mg dose - 15/42 patients had a treatment related adverse event
80 mg dose - 23/47 patients had a treatment related adverse event
100 mg dose - 47/52 patients had a treatment related adverse event

Based on this study, which of the following represents the most likely therapeutic index for this novel chemotherapeutic agent?